Bosentan is:
**Core Concept**
Bosentan is an endothelin receptor antagonist, specifically a dual endothelin receptor antagonist (ET_A and ET_B) used in the treatment of pulmonary arterial hypertension (PAH) and portopulmonary hypertension. It works by blocking the action of endothelin-1, a potent vasoconstrictor peptide, thereby reducing pulmonary vascular resistance and improving symptoms in patients with PAH.
**Why the Correct Answer is Right**
Bosentan exerts its effects by binding to endothelin receptors on the surface of pulmonary artery smooth muscle cells, preventing the vasoconstrictive effects of endothelin-1. This leads to vasodilation of the pulmonary arteries and a decrease in pulmonary vascular resistance. Bosentan also has antiproliferative effects, reducing the growth of pulmonary artery smooth muscle cells and further contributing to its therapeutic effects in PAH.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because bosentan is not a phosphodiesterase inhibitor, which is a class of drugs used to treat PAH by increasing the levels of cyclic guanosine monophosphate (cGMP) in the pulmonary arteries.
**Option B:** This option is incorrect because bosentan is not a prostacyclin analogue, which is another class of drugs used to treat PAH by stimulating the production of prostacyclin and increasing cAMP levels in the pulmonary arteries.
**Option C:** This option is incorrect because bosentan is not a nitric oxide donor, which is a class of drugs used to treat PAH by increasing the levels of nitric oxide in the pulmonary arteries, leading to vasodilation.
**Clinical Pearl / High-Yield Fact**
Bosentan is a dual endothelin receptor antagonist that is used in the treatment of PAH and portopulmonary hypertension. It is also used in the treatment of pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH). Bosentan is contraindicated in pregnancy due to its teratogenic effects.
**Correct Answer:** C. Bosentan is an endothelin receptor antagonist.